Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Depreciation and Depletion (2024 - 2025)

United Therapeutics (UTHR) has disclosed Depreciation and Depletion for 2 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 17.01% to $22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.7 million through Dec 2025, up 18.3% year-over-year, with the annual reading at $84.7 million for FY2025, 18.3% up from the prior year.
  • Depreciation and Depletion hit $22.7 million in Q4 2025 for United Therapeutics, up from $21.5 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $22.7 million in Q4 2025 to a low of $14.8 million in Q1 2024.